Business Wire

Crayon redefines cloud performance with breakthrough processor technology

30.9.2024 09:02:00 CEST | Business Wire | Press release

Share

Unlocking savings on cloud compute costs with AMD EPYC™ CPU-powered server processors

Crayon, a global leader in IT services and innovation, today announced its continued collaboration with AMD to revolutionize cloud performance using AMD EPYC™ server processors. This collaboration enables businesses to unlock unprecedented levels of efficiency by optimizing the physical processors powering their cloud infrastructure, delivering both performance and cost savings beyond traditional virtualization.

“As a leader in cost optimization, FinOps, and software asset management (SAM), we've consistently focused on helping customers maximize the value of their technology investments while reducing costs,” said Gudmundur Adalsteinsson, Crayon’s Chief Revenue Officer.

“Our advanced FinOps practices ensure that organizations maintain financial accountability in cloud environments, providing real-time visibility and control over cloud spend across Azure, AWS, and GCP. This, combined with our collaboration with AMD, elevates our mission further. With the establishment of the Crayon Cloud Performance Lab, we ensure that our customers can fully leverage the most optimal processors and configurations, specifically tuned to their individual workloads, to enhance performance and reduce costs. AMD EPYC server processors deliver leadership performance for Enterprise, HPC, and AI workloads with advanced security features,” he continued.

Crayon has recently established its own Performance Lab, a dedicated unit tasked with conducting performance tests on different workloads using AMD EPYC server processors. The Lab utilizes standard test scripts and processes to validate test results and provide clients with detailed, accurate workload performance comparisons across various cloud providers and operating systems to determine optimal cloud configurations. The Lab's independent testing confirms the exceptional efficiency of AMD processors, offering clients a reliable assessment of potential cost savings and performance gains.

Rigorous testing by the Performance Lab has validated that AMD EPYC server processors deliver exceptional efficiency, helping reduce the power consumption needed for high-performance workloads. Businesses can save on their cloud compute estate by considering underlying physical processors and moving beyond a purely virtualized approach. This makes the Crayon-AMD collaboration especially relevant for organizations looking to reduce operational costs while maximizing the power of their cloud environments.

“The ability to harness the full potential of AMD EPYC server processors is a game-changer for businesses aiming to reduce energy consumption and increase performance,” said Blaine Noel, Sr. Director, at AMD. “By optimizing cloud compute resources, combined with a traditional on-premise deployment model, companies can achieve significant cost savings and modernize their infrastructure.”

This collaboration marks a critical step in the evolution of cloud computing, providing businesses with the tools they need to stay ahead in a fast-changing landscape. As workloads become increasingly complex, Crayon and AMD are leading the charge in helping ensure cloud environments are ready to meet those demands efficiently.

AMD, the AMD Arrow logo, EPYC, and combinations thereof are trademarks of Advanced Micro Devices, Inc.

About Crayon

Headquartered in Oslo, Norway, with a global presence spanning 46 countries and a dedicated team of 4,000 professionals, Crayon champions IT optimization and innovation. We are a customer-first company providing return on investment on software and cloud spend by empowering our customers to strategically acquire and optimize software investments, embrace cloud and AI technologies, and drive innovation through enhanced efficiency.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240930779641/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye